
COPYRIGHT © ABCELLERA
November 10, 2026
Corporate Overview
We are a clinical-stage biotech company focused on developing novel antibody
Liquidity
We continue to maintain a strong liquidity position to execute on our strategy
Programs
We are advancing an internal pipeline of programs.
$790M+
in total cash balances & marketable securities
20+
internal program starts
$100M+
in available government funding
5
programs in IND-enabling activities
3yrs+
of funding for pipeline investments
2
molecules in the clinic1
medicinesPlatform ~$1B
300K+sq ft
Founded: 2012
Employees: ~600
Locations: Vancouver & Montreal, Canada
We have built a fully integrated antibody drug platform from discovery to clinical manufacturing and development.
in total platform
investments
of research and manufacturing facilities
Sydney, Australia
Partnerships 100+
40+ 12
COPYRIGHT © ABCELLERA
IPO: December 2020
We formed partnerships with companies that bring
novel biology or technology.
partner-led programs supported
partners
molecules in the clinic2
As of September 30, 2026
As of September 30, 2026
AbCellera-led programs
Partner-led programs, including under Trianni licenses, understood to be progressing in the clinic.
3
100+ 12
Corporate Overview
Our platform was built through 10+ years of drug discovery partnerships
Since 2014, we have partnered with some of the industry's most innovative pharma and biotech companies. Partnerships were a driver for R&D, and provided near-term revenue in the form of
research payments and long-term potential revenue in the form of royalty stakes in those drug programs.
COPYRIGHT © ABCELLERA
In 2023, we shifted our focus from partnerships to advancing a pipeline of internal programs.
partner-led programs supported
molecules from partner-led programs are understood to be progressing in the clinic*
AbbVie
*As of September 30, 2026
4
STRATEGY
Corporate Overview
Use our competitive advantage in antibody drug creation to build a pipeline of differentiated assetsDiscovery for GPCR and ion channel targets
Novel modalities, including multispecifics and ADCs
Indication agnostic
COPYRIGHT © ABCELLERA
5
ABCELLERA PIPELINE
PROGRAMS TARGET INDICATION THERAPEUTIC AREA STAGE
Corporate Overview
IND-Enabling Phase 1 Phase 2 Phase 3
ABCL635 | NK3R | VMS due to menopause | Endocrinology & Women's Health |
VMS due to breast cancer treatment | Oncology | ||
VMS due to prostate cancer treatment | Oncology | ||
ABCL992 | NK3R | VMS | Endocrinology |
ABCL575 | OX40L | Atopic Dermatitis | Immunology & Inflammation |
ABCL688 | Undisclosed GPCR / ion channel | Undisclosed | Autoimmunity |
ABCL386 | Undisclosed | Undisclosed | Oncology |
ABCL385 | Undisclosed | Undisclosed | Oncology |
ABCL646 | Undisclosed Ion channel | Undisclosed | Undisclosed |
COPYRIGHT © ABCELLERA
6 As of September 30, 2026
2026 PRIORITIES
In Q3, we advanced ABCL992, ABCL385, and ABCL646 into the pipeline, completing all 2026 prioritiesCorporate Overview
ABCL635 Phase 2 clinical trial
top-line readout on Aug 10, 2026
ABCL575 Phase 1 clinical trial
top-line readout on Nov 9, 2026
ABCL688 progressing through
IND-enabling activities
ABCL386 progressing through
IND-enabling activities
Nominate at least 1 additional development candidate for
IND-enabling activities
COPYRIGHT © ABCELLERA
7
Internal Programs
8
COPYRIGHT © ABCELLERA Corporate Overview
Internal Programs ABCL635
9
COPYRIGHT © ABCELLERA Corporate Overview
ABCL635
ABCL635 is an investigational potential first-in-class antibody for the non-hormonal treatment of moderate and severe vasomotor symptomsTarget
Corporate Overview
Neurokinin 3 receptor (NK3R)
Target Type
G protein-coupled receptor (GPCR)
Indication
Moderate and severe vasomotor symptoms (VMS) due to menopause
Status
Phase 2
COPYRIGHT © ABCELLERA
First GPCR-targeting antibody from our platform to advance into our internal pipeline
Additional opportunities
in oncology
10
ABCL635 Opportunity
ABCL635 could help to address a large unmet need for the treatment of VMS due to menopause and cancer treatments
VMS Due to Menopause
Corporate Overview
4+ years
is the median duration for vasomotor symptoms post final
Market Opportunity VMS Due to Menopause
1M+ women
could benefit from safe and effective non-hormonal treatments.3
VMS Due to Cancer Treatment
Many patients experience VMS during cancer treatment
menstrual period.1
Symptoms: Sudden and intense feeling of heat that leads to sweating, chills, and interrupted sleep.2
~12M women in
the US experience moderate-to-severe VMS.3
$6B+
>6M of which
seek treatment.
~20% for whom
3 hormone therapy is unsuitable due to contraindications or other factors.4
that includes hormone suppression for:
Breast cancer
Prostate cancer
Ovarian cancer
COPYRIGHT © ABCELLERA
Total Addressable Market estimated for non-hormonal treatments assuming only current small-molecule gross prices as >$5K per patient per year.5
Avis et al., JAMA Intern Med., 2015.
Nappi et al., Menopause, 2021.
Management estimate based on US census data, 2023; Todorova et al., Menopause, 2023; Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022.
Management estimate based on Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022.
Management estimate based on Wholesale Acquisition Cost of Veozah and Lynkuet (accessed from Micromedex Red Book) and above sources.
11 Actual market size may differ.
ABCL635
Market Opportunity
Over 1 million women in the US are estimated to need a non-hormonal treatment for moderate and severe VMS due to menopause
Contraindicated for
MHT
Corporate Overview
MHT not tolerated
1M+
~20% in need of non-hormonal treatment2
~12M
women in the US with moderate-to-severe
VMS due to menopause1
6M+
>50% seek treatment1
<50% do not seek treatment 1
Eligible for MHT
80% successfully treated with or remaining eligible for MHT2
COPYRIGHT © ABCELLERA
Management estimate based on US census data, 2023; Todorova et al., Menopause, 2023; Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022.
Management estimate based on Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022. Actual market size may differ.
12
ABCL635 Science
NK3R antagonists are effective, non-hormonal options for VMSCorporate Overview
Reproductive State
COPYRIGHT © ABCELLERA
13
ABCL635 Science
NK3R antagonists are effective, non-hormonal options for VMSCorporate Overview
Menopause
COPYRIGHT © ABCELLERA
14
ABCL635 Science
NK3R antagonists are effective, non-hormonal options for VMSCorporate Overview
Treatment
COPYRIGHT © ABCELLERA
15 Proposed mechanism of action for ABCL635 based on AbCellera clinical data and published literature.
ABCL635 Differentiation
Recently approved NK3R therapies are building the market
Fezolinetant
Corporate Overview
Small molecule NK3R antagonist
Elinzanetant
Small molecule NK3R and NK1R antagonist
Stage
Approved by US FDA on May 12, 2023
Stage
Approved by US FDA October 24, 2025
Dosing
Daily oral treatment
Dosing
Daily oral treatment
Effective in reducing severity and frequency of VMS.
COPYRIGHT © ABCELLERA
Boxed warning for liver toxicity. Requires liver monitoring.
Effective in reducing severity and frequency of VMS.
Warnings for CNS depressant effect, daytime impairment, and liver enzyme elevation. Requires liver monitoring.
CNS: Central nervous system
16
ABCL635 Development
ABCL635 Phase 1 data supported advancing to Phase 2
SAFETY/TOLERABILITY ENDPOINT PHARMACOKINETIC ENDPOINT PHARMACODYNAMIC ENDPOINT
Corporate Overview
Favorable tolerability profile with no observed liver toxicity
All doses tested generally well tolerated
PK profile supports once monthly subcutaneous dosing
Estimated half-life of ~24 days
Biomarker data suggests strong and sustained engagement of NK3R
Demonstrated suppression of testosterone, LH, and FSH
ABCL635 PHASE 2 DOSE SELECTION
COPYRIGHT © ABCELLERA
A 600 mg SC dose administered once best approximates 300 mg SC at steady state*
and is being evaluated in the Phase 2 study
SC: subcutaneous.
* Based on a comparison of predicted Cmax at steady state of a 300 mg dose once every 4 weeks, vs. the Cmax from a single dose of 600 mg.
ABCL635 Differentiation
Phase 2 data at week 4 suggest ABCL635 has the potential to be a first-in-class non-hormonal treatment for moderate and severe VMS
Corporate Overview
Markedly improved efficacy data compared to available
non-hormonal therapies
Data supports an improved safety profile with reduced liver and gastrointestinal findings
Dosing convenience with long-acting subcutaneous
self-injection
COPYRIGHT © ABCELLERA
DISCLAIMER: Information provided above is for illustrative purposes only and no head-to-head clinical trials have been conducted. Differences exist between study or trial designs and subject characteristics, and caution should be
exercised when comparing data across trials.
ABCL635 Phase 2 Top-line Data
at Week 4
19
COPYRIGHT © ABCELLERA Corporate Overview
ABCL635 Phase 2 is a randomized, double-blind,
placebo-controlled, multicenter trial in postmenopausal women
Participants
Corporate Overview
Key inclusion criteria Endpoints
Efficacy analysis population/ Primary analysis methodology
Phase 2 Study Trial Design
N ~ 80 planned
92 postmenopausal women with moderate-to-severe VMS
N=46 per cohort
Comparable to Phase 3 entry criteria for approved NK3R small molecules Age 40-75 years
VMS frequency, VMS severity, patient-reported outcome measures, safety, pharmacokinetics Intent to treat population at 4 weeks
MMRM analyses except for patient global impression of change (Mann-Whitney U test)
Placebo-controlled treatment period Optional open-label extension (OLE)
Open-Label Extension 600 mg SC
ABCL635 600 mg SC
(N=46)
Screening
Study design
COPYRIGHT © ABCELLERA
R
Placebo
(N=46)
20 NK3R: Neurokinin 3 Receptor; MMRM: Mixed Models for Repeated Measures; SC: subcutaneous. Clinicaltrials.gov ID: NCT07118891.
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
